Publication Date
| In 2025 | 0 |
| Since 2024 | 2 |
Descriptor
| Cancer | 2 |
| Medical Research | 2 |
| Bayesian Statistics | 1 |
| Feasibility Studies | 1 |
| Medical Care Evaluation | 1 |
| Medical Services | 1 |
| Meta Analysis | 1 |
| Oncology | 1 |
| Program Implementation | 1 |
| Reaction Time | 1 |
| Research Methodology | 1 |
| More ▼ | |
Source
| Research Synthesis Methods | 2 |
Author
| Alessandro Gasparini | 1 |
| Alex J. Sutton | 1 |
| Bruno Laviolle | 1 |
| Clara Locher | 1 |
| Laura Caquelin | 1 |
| Lucas Poulain | 1 |
| Michael J. Crowther | 1 |
| Moreno Ursino | 1 |
| Neil Hawkins | 1 |
| Nicola J. Cooper | 1 |
| Pauline Badra | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
| Information Analyses | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkSuzanne C. Freeman; Alex J. Sutton; Nicola J. Cooper; Alessandro Gasparini; Michael J. Crowther; Neil Hawkins – Research Synthesis Methods, 2024
Background: Traditionally, meta-analysis of time-to-event outcomes reports a single pooled hazard ratio assuming proportional hazards (PH). For health technology assessment evaluations, hazard ratios are frequently extrapolated across a lifetime horizon. However, when treatment effects vary over time, an assumption of PH is not always valid. The…
Descriptors: Cancer, Medical Research, Bayesian Statistics, Meta Analysis
Laura Caquelin; Pauline Badra; Lucas Poulain; Bruno Laviolle; Moreno Ursino; Clara Locher – Research Synthesis Methods, 2024
This study aimed to assess the feasibility of applying two recent phase I meta-analyses methods to protein kinase inhibitors (PKIs) developed in oncology and to identify situations where these methods could be both feasible and useful. This ancillary study used data from a systematic review conducted to identify dose-finding studies for PKIs. PKIs…
Descriptors: Oncology, Cancer, Medical Care Evaluation, Medical Research
